PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28137980-1 2017 The HIV protease inhibitor Nelfinavir (NFV) inhibits PI3K/AKT and MAPK/ERK signaling pathways, emerging targets in thyroid cancers. Nelfinavir 27-37 AKT serine/threonine kinase 1 Homo sapiens 58-61 34136086-5 2021 The IU-TAB-1 cell line was noted to be resistant to everolimus (mTORC1 inhibitor) and sensitive to nelfinavir (AKT1 inhibitor) across the endpoints measured. Nelfinavir 99-109 AKT serine/threonine kinase 1 Homo sapiens 111-115 34136086-6 2021 Sensitivity to nelfinavir was due to the IU-TAB-1 cell line"s gain-of function (GOF) mutation in PIK3CA and amplification of genes observed from array comparative genomic hybridization (aCGH), including AURKA, ERBB2, KIT, PDGFRA and PDGFB, that are known upregulate AKT, while resistance to everolimus was primarily driven by upregulation of downstream signaling of KIT, PDGFRA and PDGFB in the presence of mTORC1 inhibition. Nelfinavir 15-25 AKT serine/threonine kinase 1 Homo sapiens 266-269 35204223-8 2022 Furthermore, although activated in cells that survived standalone FUS, pre-sensitization with CDDO-me and/or nelfinavir suppressed both total and activated (phosphorylated) NF-kappaB and Akt protein levels. Nelfinavir 109-119 AKT serine/threonine kinase 1 Homo sapiens 187-190 35387819-3 2022 This trial will investigate the impact of nelfinavir, a protease inhibitor that targets the protein kinase B (AKT) pathway on disease-free survival (DFS). Nelfinavir 42-52 AKT serine/threonine kinase 1 Homo sapiens 110-113 28137980-10 2017 NFV (20 microM) decreased the levels of total and p-AKT in PTEN-deficient FTC133 cells. Nelfinavir 0-3 AKT serine/threonine kinase 1 Homo sapiens 52-55 17785575-10 2007 Akt was variably inhibited by HIV protease inhibitors, but nelfinavir caused the greatest inhibition of endogenous and growth factor-induced Akt activation. Nelfinavir 59-69 AKT serine/threonine kinase 1 Homo sapiens 141-144 27280849-2 2016 Although the molecular mechanism by which nelfinavir exerts antitumor activity is still unknown, its effects have been related to Akt inhibition. Nelfinavir 42-52 AKT serine/threonine kinase 1 Homo sapiens 130-133 27280849-7 2016 Nelfinavir treated tumor cells also displayed a downregulation of the Akt pathway due to disruption of the Akt-HSP90 complex, and subsequent degradation of Akt. Nelfinavir 0-10 AKT serine/threonine kinase 1 Homo sapiens 70-73 27280849-7 2016 Nelfinavir treated tumor cells also displayed a downregulation of the Akt pathway due to disruption of the Akt-HSP90 complex, and subsequent degradation of Akt. Nelfinavir 0-10 AKT serine/threonine kinase 1 Homo sapiens 107-110 27280849-7 2016 Nelfinavir treated tumor cells also displayed a downregulation of the Akt pathway due to disruption of the Akt-HSP90 complex, and subsequent degradation of Akt. Nelfinavir 0-10 AKT serine/threonine kinase 1 Homo sapiens 107-110 25327558-12 2014 In peripheral blood mononuclear cells, Nelfinavir inhibited AKT and induced markers of ER stress. Nelfinavir 39-49 AKT serine/threonine kinase 1 Homo sapiens 60-63 23647753-0 2013 Phase I trial of the combination of the Akt inhibitor nelfinavir and chemoradiation for locally advanced rectal cancer. Nelfinavir 54-64 AKT serine/threonine kinase 1 Homo sapiens 40-43 19480971-4 2009 We are in the process of starting a clinical trial in H&N cancer patients using nelfinavir (NFV) (which inhibits Akt) and it would be important to know the effect of HPV on radiation response +/- NFV. Nelfinavir 84-94 AKT serine/threonine kinase 1 Homo sapiens 117-120 18509182-6 2008 Phospho-Akt downregulation by nelfinavir was monitored by immunoblotting in patient leukocytes. Nelfinavir 30-40 AKT serine/threonine kinase 1 Homo sapiens 8-11 24418752-6 2014 Saquinavir, nelfinavir and lopinavir were likewise cytotoxic against primary AML cells, triggered PS-induced apoptosis, inhibited AKT-phosphorylation and showed synergistic cytotoxicity with bortezomib and carfilzomib at low micromolar concentrations. Nelfinavir 12-22 AKT serine/threonine kinase 1 Homo sapiens 130-133 22271897-10 2012 Cell death triggered by nelfinavir treatment correlated with decreased phosphorylation of AKT, STAT3 and ERK1/2. Nelfinavir 24-34 AKT serine/threonine kinase 1 Homo sapiens 90-93 22338016-0 2012 Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma. Nelfinavir 27-37 AKT serine/threonine kinase 1 Homo sapiens 0-3 22338016-10 2012 Nelfinavir and MK-2206, chosen for their Akt-inhibitory properties, yielded synergistic inhibition of cell viability in combination with rapamycin in DLBCL cell lines, and potently inhibited phosphorylation of Akt and downstream targets of activated mTOR. Nelfinavir 0-10 AKT serine/threonine kinase 1 Homo sapiens 41-44 22338016-10 2012 Nelfinavir and MK-2206, chosen for their Akt-inhibitory properties, yielded synergistic inhibition of cell viability in combination with rapamycin in DLBCL cell lines, and potently inhibited phosphorylation of Akt and downstream targets of activated mTOR. Nelfinavir 0-10 AKT serine/threonine kinase 1 Homo sapiens 210-213 18000394-6 2008 Nelfinavir blocks growth factor receptor activation and decreases growth factor-induced and endogenous Akt signaling. Nelfinavir 0-10 AKT serine/threonine kinase 1 Homo sapiens 103-106 17483362-3 2007 We examined whether PTEN deficiency leads to radioresistance and whether this can be reversed by nelfinavir, a protease inhibitor that decreases Akt signaling. Nelfinavir 97-107 AKT serine/threonine kinase 1 Homo sapiens 145-148 17483362-4 2007 Nelfinavir decreased Akt phosphorylation and enhanced radiosensitization in U251MG and U87MG glioblastoma cells, both of which are PTEN deficient. Nelfinavir 0-10 AKT serine/threonine kinase 1 Homo sapiens 21-24 17483362-7 2007 This epistasis-type analysis suggests that the nelfinavir acts along the Akt pathway to radiosensitize cells. Nelfinavir 47-57 AKT serine/threonine kinase 1 Homo sapiens 73-76 17133272-0 2006 NFV, an HIV-1 protease inhibitor, induces growth arrest, reduced Akt signalling, apoptosis and docetaxel sensitisation in NSCLC cell lines. Nelfinavir 0-3 AKT serine/threonine kinase 1 Homo sapiens 65-68 17460771-0 2007 The HIV protease inhibitor nelfinavir downregulates Akt phosphorylation by inhibiting proteasomal activity and inducing the unfolded protein response. Nelfinavir 27-37 AKT serine/threonine kinase 1 Homo sapiens 52-55 17460771-8 2007 Furthermore, our data indicate that nelfinavir decreases Akt phosphorylation by triggering this response. Nelfinavir 36-46 AKT serine/threonine kinase 1 Homo sapiens 57-60 17460771-9 2007 These findings may have important implications in understanding how nelfinavir may increase radiation sensitivity and also result in downregulation of the PI3K/Akt pathway. Nelfinavir 68-78 AKT serine/threonine kinase 1 Homo sapiens 160-163 17132220-6 2006 Downregulation of P-Akt decreased VEGF secretion in a manner similar to that of nelfinavir, but the combination of the two had no greater effect, consistent with the idea that nelfinavir decreases VEGF through the PI3K/Akt pathway. Nelfinavir 176-186 AKT serine/threonine kinase 1 Homo sapiens 219-222 15168016-0 2004 Nelfinavir-induced insulin resistance is associated with impaired plasma membrane recruitment of the PI 3-kinase effectors Akt/PKB and PKC-zeta. Nelfinavir 0-10 AKT serine/threonine kinase 1 Homo sapiens 123-130 16166302-4 2005 Five first-generation HPIs were subsequently tested and three of the five (amprenavir, nelfinavir, and saquinavir but not ritonavir or indinavir) inhibited Akt phosphorylation at Ser473 at serum concentrations routinely achieved in HIV patients. Nelfinavir 87-97 AKT serine/threonine kinase 1 Homo sapiens 156-159 16166302-6 2005 In addition, in vivo, doses of amprenavir or nelfinavir comparable with the therapeutic levels achieved in HIV patients were sufficient to down-regulate phosphorylation of Akt in SQ20B and T24 xenografts. Nelfinavir 45-55 AKT serine/threonine kinase 1 Homo sapiens 172-175